Veradermics reports Q3 2026 results, $798.4 million cash, runway into 2030Nov 10Clinical readoutAbsci CorpVDPHL01Updated
Veradermics reports positive Phase 3 topline data for oral minoxidil in male hair lossOct 19Clinical readoutminoxidilVDPHL01
Veradermics reports Q2 2026 results, completes enrollment in female pattern hair loss trialAug 11Quarterly updateVeradermics, Inc.
Veradermics files S-1 to register 16.8 million resale shares from PIPE investors and insidersAug 7FinancingVeradermics, Inc.
Veradermics reports positive Phase 2 data for oral VDPHL01 in female hair lossJul 15Clinical readoutVDPHL01Veradermics, Inc.